Nano laser vs phacoemulsification for routine cataract surgery

Session Details

Session Title: Laser-Assisted Cataract Surgery (Femto and Other Types of Lasers)

Session Date/Time: Monday 12/09/2016 | 14:00-15:30

Paper Time: 15:16

Venue: Hall C3

First Author: : G.Sauder GERMANY

Co Author(s): :                        

Abstract Details

Purpose:

To assess the amount of trauma and energy level of latest stage Nanolaser versus standard phakoemulsification for routine cataract surgery.

Setting:

Charlottenklinik eye hospital, Stuttgart Germany. Randomized, prospective, blind, clinical trial.

Methods:

60 patients for routine cataract surgery were randomly distributed in a Nanolaser group (NLG) and a phako group (PG). Preoperatively the density of cataracts were described by two physicians with LOCS grade. Surgery was performed by one experienced surgeon. Main outcome measurements were endothelial cell loss, corneal pachymetry and macular OCT a the 1st postoperative day and amount of energy used for cataract removal. Moreover the speed of visual recovery was measured in the first hour postoperatively.

Results:

The energy level for cataract removal as 1.84 +/- 0.41 J in the NLG and 10.22 +/- 0.86 J in the PG. Endothelial cell loss was 4% lower in the NLG in a follow up period of 3 month. The increase of corneal pachymetry was 30.4 µm in the NLG and 54.6 µm in the PG, increase of macular OCT was not statistically different in both groups respectively. Speed of visual recovery within one hour after surgery was significantly faster ( 2 snellen lines) in the Nanolaser group.

Conclusions:

With the newest stage of development of the Nano Laser, consisting of a decreased laser pulse duration and a new handpiece design, most parameter for intraoperative trauma during routine cataract surgery were better in the Nanolaser group as in the Phako group. Especially visual recovery and energy consumption during surgery were much better in the NLG. Longer follow up periods and data of more patients have to proof the benefit for the patients.

Financial Disclosure:

NONE